313 related articles for article (PubMed ID: 14678865)
1. Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Fonseca V
Am J Med; 2003 Dec; 115 Suppl 8A():42S-48S. PubMed ID: 14678865
[TBL] [Abstract][Full Text] [Related]
2. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Hollenberg NK
Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
Wilding J
Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
Granberry MC; Hawkins JB; Franks AM
Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Seufert J; Lübben G; Dietrich K; Bates PC
Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
[TBL] [Abstract][Full Text] [Related]
6. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
Meriden T
Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
[TBL] [Abstract][Full Text] [Related]
7. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Purnell JQ; Weyer C
Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
[TBL] [Abstract][Full Text] [Related]
8. [Obesity, insulin resistance and the implication of thiazolidinediones].
Oguma Y; Kataoka K
Nihon Rinsho; 2000 Feb; 58(2):411-5. PubMed ID: 10707567
[TBL] [Abstract][Full Text] [Related]
9. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
10. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
11. Impact of weight gain on outcomes in type 2 diabetes.
Ross SA; Dzida G; Vora J; Khunti K; Kaiser M; Ligthelm RJ
Curr Med Res Opin; 2011 Jul; 27(7):1431-8. PubMed ID: 21599553
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
13. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.
Kushner RF; Sujak M
Obesity (Silver Spring); 2009 May; 17(5):1017-22. PubMed ID: 19180065
[TBL] [Abstract][Full Text] [Related]
14. The patient with diabetes mellitus and heart failure: at-risk issues.
Giles TD
Am J Med; 2003 Dec; 115 Suppl 8A():107S-110S. PubMed ID: 14678875
[TBL] [Abstract][Full Text] [Related]
15. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
Bell DS
Postgrad Med; 2003 May; Spec No():35-44. PubMed ID: 12785130
[TBL] [Abstract][Full Text] [Related]
17. The mode of action of thiazolidinediones.
Hauner H
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
Vasudevan AR; Balasubramanyam A
Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
[TBL] [Abstract][Full Text] [Related]
20. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]